Project Grant K99AR084572
- Federal Project Grant Award Summary New York University School of Medicine received a $109,076 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective December 22, 2025, with a completion date of August 31, 2028. The award supports a research initiative investigating the role of skin pathobionts, specifically Staphylococcus aureus, in the pathogenesis and progression of...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $5.18 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, San Diego, effective September 5, 2025, through August 31, 2029. This research project investigates the relationship between skin microbiota colonization patterns and the development of allergic diseases, specifically atopic dermatitis (AD) and food allergy...
- This Project Grant award of $528,558 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports a five-year research initiative at Icahn School of Medicine at Mount Sinai, commencing September 1, 2025 and concluding August 31, 2030. The research addresses critical gaps in understanding treatment resistance and paradoxical inflammatory side effects associated with dupilumab...
- Federal Grant Award Summary The University of Pennsylvania received a $184,680 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), with an award date of August 12, 2025, and completion date of July 31, 2026. This K99/R00 career development award supports biomedical research investigating the role of itch-sensing neurons in skin immunity against helminth parasites, specifically...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Regents of the University of California, San Francisco a Project Grant of $189,376 under the Allergy and Infectious Diseases Research program (CFDA 93.855) with an award date of October 24, 2025, and a completion date of November 6, 2026. The research project, titled "Unraveling Skin Microbiota-Immune Interactions That Drive Early Life Commensal Tolerance," investigates the...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $716,281 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Boston Children's Hospital, with an award date of July 24, 2025 and completion date of June 30, 2030. This research project investigates the mechanisms by which T regulatory cells (Tregs) control allergic skin inflammation, with particular focus on how deficiencies in the DOCK8 protein...
- The federal Project Grant award of $198,782 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports the development of a platform to investigate interactions between the skin microbiome and skin cell populations using genetically modified 3D in vitro models. The goal is to enable the examination of host-microbe interactions at scale to better understand the mechanisms...
- Federal Project Grant Award Summary The University of California, San Francisco (UCSF) received a $243,950 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop personalized predictive models for atopic dermatitis disease progression and comorbidities. The research initiative, which commenced on September 19, 2025, and will conclude on June 30,...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Icahn School of Medicine at Mount Sinai a $4.13 million Project Grant effective September 1, 2025, through August 31, 2028, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The funded research initiative, "Uncovering Novel Microbial Factors That Enhance Wound Repair," addresses the significant public health burden of acute...
- Federal Grant Award Summary New York University School of Medicine received a $208,332 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded June 16, 2025, with completion anticipated by May 31, 2030. The grant funds investigative research into host-pathogen interactions during Staphylococcus aureus spine infections, specifically examining how the pathogen evades human innate immune...
STAPHYLOCOCCUS AUREUS INDUCED ITCH AND NEURO-IMMUNE SIGNALING IN SKIN INFLAMMATION AND ATOPIC DERMATITIS - PROJECT SUMMARY ITCH IS AN UNPLEASANT SENSATION THAT ELICITS THE DESIRE OR THE REFLEX TO SCRATCH. CHRONIC ITCH IS A CHARACTERISTIC SYMPTOM OF ATOPIC DERMATITIS (AD), ONE OF THE MOST COMMON INFLAMMATORY SKIN DISEASES AND A SIGNIFICANT CAUSE OF PATIENT SUFFERING. ANOTHER HALLMARK OF AD IS MICROBIAL DYSBIOSIS WITH INCREASED STAPHYLOCOCCUS AUREUS ON THE SKIN. OVER 90% OF AD SKIN LESIONS ARE POSITIVE FOR S. AUREUS. HERE, I PROPOSE TO INVESTIGATE THE ROLE OF S. AUREUS- INDUCED ITCH AND NEURO-IMMUNE SIGNALING IN DRIVING SKIN BARRIER DAMAGE AND IMMUNE RESPONSES. MY PRELIMINARY DATA SHOW THAT EPICUTANEOUS EXPOSURE TO S. AUREUS INDUCES ROBUST ITCH BEHAVIORS (SPONTANEOUS ITCH AND ALLOKNESIS) AND RESULTING SKIN PATHOLOGY IN MICE. I IDENTIFIED THE SERINE PROTEASE V8 (SSPA) AS A CRITICAL FACTOR IN MEDIATING BOTH ITCH AND DERMATITIS. V8 DIRECTLY ACTIVATES ITCH NEURONS THROUGH ITS RECEPTOR PROTEINASE-ACTIVATED RECEPTOR 1 (PAR1). I HYPOTHESIZE THAT S. AUREUS AND V8 PROTEASE-INDUCED ITCH TRIGGER SKIN INFLAMMATION AND IMPACT NEUROIMMUNE SIGNALING. IN SPECIFIC AIM 1, I WILL DEFINE THE CONTRIBUTION OF V8 PROTEASE, NEURONS, AND ITCH TO SKIN IMMUNE RESPONSES. I WILL INOCULATE MICE WITH WILDTYPE OR ISOGENIC V8-DEFICIENT (SSPA) S. AUREUS STRAINS AND PERFORM DETAILED FLOW CYTOMETRY TO PROFILE THE SKIN IMMUNE POPULATION. I WILL UTILIZE GENETIC APPROACHES TO ABLATE SPECIFIC SKIN-INNERVATING NEURONS (TRPV1+ AND MRGPRD+) TO ASSAY THEIR ROLE IN ITCH AND INFLAMMATION. I WILL TREAT MICE WITH THE PAR1 ANTAGONIST VORAPAXAR TO DETERMINE HOW ITCH AND SCRATCHING DRIVE SKIN IMMUNE RESPONSES. IN SPECIFIC AIM 2, I WILL CHARACTERIZE THE NEURONAL RESPONSE TO S. AUREUS AND V8 PROTEASE. ITCH IS MEDIATED BY DORSAL ROOT GANGLIA (DRG) SENSORY NEURONS. I WILL PERFORM RNA-SEQUENCING OF DRGS TO IDENTIFY TRANSCRIPTIONAL CHANGES FOLLOWING S. AUREUS EXPOSURE. I WILL USE REPORTER MICE (NAV1.8-CRE/TDTOMATO) TO LABEL SENSORY NEURONS AND FOR WHOLE MOUNT CONFOCAL MICROSCOPY TO QUANTIFY EPIDERMAL NEURON DENSITY IN NAIVE AND S. AUREUS EXPOSED MICE. I WILL CULTURE DRG NEURONS WITH S. AUREUS OR PURIFIED V8 PROTEASE AND PERFORM ELISAS TO MEASURE SECRETED NEUROPEPTIDES. I HYPOTHESIZE THAT S. AUREUS AND V8-INDUCED ITCH/SCRATCHING CONTRIBUTE SIGNIFICANTLY TO SKIN PATHOLOGY IN AD. IN SPECIFIC AIM 3, I WILL UTILIZE TMEM79-/- MOUSE MODEL OF AD TO INVESTIGATE MICROBE-NEURON INTERACTIONS. I WILL COLONIZE TMEM79-/- MICE WITH WT AND SSPA S. AUREUS AND MEASURE ITCH AND DERMATITIS. I WILL SURGICALLY DENERVATE THE BACK SKIN OF TMEM79-/- MICE AND PERFORM FLOW CYTOMETRY AND MULTIPLEX ELISA TO IDENTIFY IMMUNE CHANGES. I WILL PERFORM 16S SEQUENCING OF SKIN SAMPLES FROM CONTROL AND DENERVATED TMEM79-/- MICE TO DETERMINE THE ROLE OF NEURONS IN REGULATING THE SKIN MICROBIOME IN AD SKIN. I WILL ALSO DETERMINE WHETHER S. AUREUS COLONIZATION CHANGES IN DENERVATED MICE. THIS WORK WILL REVEAL NOVEL MOLECULAR CROSSTALK BETWEEN S. AUREUS, NEURONS, AND IMMUNE CELLS IN ITCH AND AD. THE THREE AIMS OF THIS STUDY LEVERAGE MY UNIQUE SKILLSETS AND TRAINING BY COMBINING MICROBIOLOGICAL, NEUROBIOLOGICAL, AND IMMUNOLOGICAL APPROACHES. GIVEN THE IMPORTANCE OF ITCH IN AD AND OTHER SKIN DISEASES, INVESTIGATING HOW MICROBE-NEURON CROSSTALK DRIVE ITCH AND DERMATITIS COULD TRANSFORM OUR UNDERSTANDING OF HOST-MICROBE INTERACTIONS AT THE SKIN BARRIER.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $100.1k | 7/31/25 | ||
| Not listed | $100.1k | 7/26/24 |